申请人:STERLING DRUG INC.
公开号:EP0168037A2
公开(公告)日:1986-01-15
1-R-5-Ar-1,6-naphthyridin-2(1H)-ones (I) or salts thereof, where R is hydrogen or methyl, and Ar is phenyl or phenyl substituted by methyl, ethyl, methoxy, ethoxy, hydroxy, amino, acetylamino, methanesulfonylamino, bromo, chloro, fluoro, cyano or carbamyl are useful as cardiotonic agents and corresponding compounds where Ar is nitrophenyl are useful as intermediates. Also shown as intermediates, are 5-(Ar-CO)-6-[2-(di-lower-alkylamino)-ethenyl]-2(1H)-pyridinones (II) or salts thereof, where Ar is phenyl or phenyl substituted by methyl, ethyl, methoxy, ethoxy, bromo, chloro, fluoro, cyano or nitrp and 5-(Ar-CO)-6-methyl-2(1H)-pyridinones (III) where Ar is phenyl or phenyl substituted by methyl, ethyl, methoxy, ethoxy, bromo, chloro, fluoro, hydroxy, cyano or nitro; said compounds (III) where Ar is phenyl or hydroxyphenyl also are useful as cardiotonic agents. A process for preparing the compounds of formula I, comprises reacting compound (11) with formamidine or ammonia or a salt thereof.
1-R-5-Ar-1,6-萘啶-2(1H)-酮(I)或其盐,其中 R 为氢或甲基,Ar 为苯基或被甲基、乙基、甲氧基、乙氧基、羟基、氨基、乙酰氨基、甲磺酰氨基、溴基、氯基、氟基、氰基或氨甲酰取代的苯基,可用作强心剂,Ar 为硝基苯基的相应化合物可用作中间体。作为中间体的还有 5-(Ar-CO)-6-[2-(二低烷基氨基)-乙烯基]-2(1H)-吡啶酮 (II) 或其盐,其中 Ar 是苯基或被甲基、乙基、甲氧基、乙氧基、溴基、氯基、氟基、氰基取代的苯基、和 5-(Ar-CO)-6-甲基-2(1H)-吡啶酮 (III),其中 Ar 为苯基或被甲基、乙基、甲氧基、乙氧基、溴基、氯基、氟基、羟基、氰基或硝基取代的苯基;Ar 为苯基或羟基苯基的所述化合物(III)也可用作强心剂。制备式 I 化合物的工艺包括使化合物 (11) 与甲脒或氨或其盐反应。